Chemioterapia per il carcinoma pancreatico in Israele — ricevi 3 opzioni di cliniche personalizzate

The COMBAT/KEYNOTE-202 trial is an Israeli-led Phase II study combining motixafortide, pembrolizumab, and NAPOLI-1 chemotherapy. This regimen targets metastatic pancreatic ductal adenocarcinoma in patients who progressed after initial treatment. Motixafortide, developed by Israeli firm BioLineRx, increases immune cell infiltration to enhance immunotherapy efficacy.

• Core mechanism: Motixafortide blocks CXCR4 receptors to bypass the protective tumor microenvironment.
• Drug cocktail: Combines Israeli-developed motixafortide with Keytruda and three specific chemotherapy agents.
• Clinical objective: Evaluates objective response rates in patients resistant to standard gemcitabine therapies.
• Israeli innovation: BioLineRx leads this research alongside major oncology centers like Sourasky.

Bookimed Expert Insight: Israeli oncology excellence is driven by researchers like Dr. Irina Stepfansky at Sourasky Medical Center. She actively leads Phase I-III trials for advanced pancreatic cancer. Patients often access these protocols at Sourasky, which treats 40,000 cancer patients annually. This high volume allows clinics to rapidly implement novel combination therapies like motixafortide.

Patient Consensus: Patients emphasize the need to verify if breakthroughs are for curative treatment or symptom management. Many suggest consulting directly with clinicians at research hospitals to confirm trial participation.

Israel offers targeted and immunotherapy for pancreatic cancer primarily through specialized clinical trials and compassionate use programs. Leading centers like Sourasky Medical Center (Ichilov) and Hadassah utilize genetic biomarker testing, including BRCA profiling and Foundation One CDx, to identify candidates for these precision medicine treatments.

• Targeted agents: Olaparib (Lynparza) treats patients with BRCA mutations to improve maintenance outcomes.
• Immunotherapy access: Keytruda is used for patients exhibiting high microsatellite instability (MSI-H) markers.
• Innovative technology: Experimental protocols often include Alpha DaRT radiotherapy combined with systemic immune stimulants.
• Precision diagnostics: Molecular profiling identifies KRAS or MMR mutations essential for selecting targeted treatments.

Bookimed Expert Insight: Israeli oncology centers demonstrate high expertise in rare pancreatic treatments, with Sourasky (Ichilov) managing 40,000 cancer patients annually. While chemotherapy remains the baseline, experts like Dr. Irina Stepfansky lead phase 1-3 clinical studies. This high trial volume means patients often access cutting-edge drugs like KRAS inhibitors long before they reach standard global markets.

Patient Consensus: Patients emphasize that genetic testing is the critical first step for accessing advanced therapies. Many advise verifying if specific innovations like OncoSil or Alpha DaRT are available for their specific tumor stage before traveling.

Israeli clinics treat metastatic cases using a multidisciplinary approach combining aggressive systemic chemotherapy with molecular profiling and innovative radiotherapy. Leading centers like Sourasky Medical Center and Hadassah Hospital utilize advanced regimens including FOLFIRINOX and Alpha DaRT radioactive seeds to manage stage 4 disease and improve survival rates.

• Systemic therapy: The FOLFIRINOX regimen remains the standard primary treatment for metastatic pancreatic cancer cases.
• Molecular profiling: Facilities use Foundation One CDx testing to identify KRAS or BRCA genetic mutations.
• Innovative radiotherapy: Alpha DaRT seeds deliver high-dose alpha radiation directly into non-resectable metastatic tumors.
• Pain management: Specialists like Dr. Yaacov Lawrence perform celiac plexus radiosurgery for oncology pain relief.

Bookimed Expert Insight: While clinics like Sourasky Medical Center serve 40,000 cancer patients annually, the real advantage in Israel is the integration of clinical trials for non-responsive cases. Some specialists, including Dr. Irina Stepfansky, focus primarily on Phase I-III studies. This provides metastatic patients access to experimental targeted RAS-inhibitors that are often unavailable in standard clinical settings elsewhere.

Patient Consensus: Patients emphasize the importance of requesting specific anti-nausea protocols, such as ondansetron and lorazepam, which significantly improve daily life during heavy chemotherapy cycles. Many highlight that starting with neoadjuvant therapy can effectively shrink tumors enough to make surgical removal a possibility.

Specialized diagnostics in Israel utilize personalized medicine to tailor chemotherapy protocols. Oncologists use comprehensive genomic profiling, liquid biopsies, and genetic drug metabolism tests to identify actionable mutations. These advanced techniques help select the most effective agents while minimizing toxic side effects for patients.

• Genomic profiling: Next-generation sequencing analyzes tumor DNA for mutations to guide targeted therapy options.
• Liquid biopsy: Blood tests detect circulating tumor DNA to monitor efficacy without invasive procedures.
• Drug metabolism testing: Testing for DPYD and UGT1A1 genes prevents severe toxicity from specific chemotherapy.
• Molecular oncotests: Tools like Foundation One CDx identify precise biomarkers for personalized drug selection.

Bookimed Expert Insight: While basic scans are standard, Israel specializes in drug metabolism screening for pancreatic cancer. Leading centers like Sourasky Medical Center (Ichilov) prioritize DPYD gene testing before starting FOLFIRINOX. This simple genetic check prevents life-threatening reactions and is a key differentiator in Israeli oncology care.

Patient Consensus: Patients emphasize the importance of using Next-Generation Sequencing to qualify for targeted trials. They also advise using liquid biopsies as a faster alternative when traditional tissue samples are insufficient.

Israeli oncology centers utilize both neoadjuvant and adjuvant chemotherapy protocols for pancreatic cancer to improve surgical outcomes. Neoadjuvant therapy typically involves 4 to 8 months of FOLFIRINOX to shrink tumors, while adjuvant therapy addresses microscopic disease within 12 weeks after surgery.

• Neoadjuvant timeline: Treatment involves 1–2 full cycles of FOLFIRINOX over a 4–8 month period.
• Surgical window: Patients usually undergo surgery 6–8 weeks after completing their neoadjuvant chemotherapy sessions.
• Adjuvant initiation: Post-operative chemotherapy preferably starts within 12 weeks to reduce recurrence risks.
• Specialized techniques: Facilities offer advanced options like HIPEC, brachytherapy, and celiac plexus radiosurgery.

Bookimed Expert Insight: Israeli protocols increasingly favor the neoadjuvant approach for borderline resectable tumors to confirm treatment response. Sourasky Medical Center alone manages 40,000 cancer patients annually. This high volume allows doctors like Dr. Ofer Merimsky to refine specific sequences for complex cases.

Patient Consensus: Many patients emphasize that timing is critical, specifically ensuring surgery happens within the 8-week window after finishing preoperative cycles. They also suggest seeking multiple opinions to confirm if a tumor is truly resectable before starting chemotherapy.

Israel is a global hub for pancreatic cancer research, offering numerous clinical trials for advanced therapies. Leading institutions like Sourasky Medical Center and Hadassah Medical Center provide access to innovative protocols, including KRAS-targeting drugs, Alpha DaRT radiation, and personalized immunotherapy vaccines for various disease stages.

• Targeted therapies: Phase 3 trials for oral KRAS inhibitors aim to double survival times.
• Advanced radiation: Alpha DaRT trials at Hadassah show high local disease control rates.
• Personalized medicine: Doctors like Professor Ido Wolf utilize genetic testing for targeted trial matching.
• Novel devices: Non-invasive tumor-treating fields are available through FDA-approved Israeli technology.

Bookimed Expert Insight: Israeli oncology centers like Sourasky (Ichilov) function as research ecosystems where senior clinicians also serve as primary investigators. For example, Dr. Irina Stepfansky directly leads phase I-III studies. This means patients often receive treatment from the same experts who designed the trial protocols, ensuring a high level of specialized care.

Patient Consensus: Patients emphasize providing detailed pathology and imaging files early to verify eligibility. Many found that initial video consultations helped bridge the gap before traveling to Jerusalem or Tel Aviv.

In Israel, the goal of palliative chemotherapy is symptom management and delaying disease progression rather than curing the cancer. JCI-accredited centers in Tel Aviv and Jerusalem prioritize quality of life by shrinking tumors to relieve nerve pressure, managing pain, and extending survival for patients with advanced malignancies.

• Symptom management: Focuses on shrinking tumors to reduce severe pain and nerve pressure.
• Disease control: Aims to slow cancer growth to prolong life without curative intent.
• Advanced technologies: Utilization of celiac plexus radiosurgery or HIPEC to target localized symptoms.
• Comfort prioritization: Doctors often adjust treatment intensity to minimize toxic side effects for patients.

Bookimed Expert Insight: Israeli oncology centers like Sourasky often integrate genetic testing, such as Foundation One CDx, into palliative plans. This strategy helps identify targeted therapy options that might be more effective than standard chemo. Even when the goal is palliative, this precision approach can significantly improve daily functional capacity compared to broad chemotherapy protocols.

Patient Consensus: Patients emphasize that this stage focus on comfort over intensity. Many recommend using pancreatic enzymes and nerve blocks early to manage nutrition and pain independently of chemo.